Physician profile
Allison Smith
NPI 1003565425
$2,099.21
in general payments reported to CMS, 2019-2025
18 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $93.76 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $465.01 | 2025 | Tremfya |
| Abbvie INC. | $347.52 | 2025 | |
| Madrigal Pharmaceuticals | $304.79 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $257.85 | 2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $135.77 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $106.59 | 2025 | Voquezna |
| Immunogen, INC. | $80.05 | 2023 | Elahere |
| Lilly USA, LLC | $66.13 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $64.64 | 2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $62.53 | 2025 | Tremfya |
| Pfizer INC. | $56.91 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.07 | 2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $21.44 | 2025 | |
| Celltrion USA INC. | $21.44 | 2025 | Vegzelma |
| Novo Nordisk INC | $20.55 | 2025 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $18.27 | 2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $17.94 | 2025 | Dupixent |
| Kci USA, INC. | $13.71 | 2023 | Prevena, 3m Cavilon, V.A.C.Instill |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.